Epysqli Alternatives Compared
| Epysqli (eculizumab) | Ultomiris (ravulizumab) | Soliris (eculizumab) |
|
|---|
| Epysqli (eculizumab) | Ultomiris (ravulizumab) | Soliris (eculizumab) |
|
|||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Hemolytic Uremic Syndrome, Paroxysmal Nocturnal Hemoglobinuria. Epysqli may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Myasthenia Gravis, Neuromyelitis Optica Spectrum Disorder, Hemolytic Uremic Syndrome, Paroxysmal Nocturnal Hemoglobinuria. Ultomiris may also be used for purposes not listed in this... View more |
Prescription only
Prescribed for Myasthenia Gravis, Neuromyelitis Optica Spectrum Disorder, Hemolytic Uremic Syndrome, Paroxysmal Nocturnal Hemoglobinuria. Soliris may also be used for purposes not listed in this... View more |
Related suggestions Paroxysmal Nocturnal Hemoglobinuria
Hemolytic Uremic Syndrome
|
|||||||||||||||||||||||
| More about Epysqli (eculizumab) | More about Ultomiris (ravulizumab) | More about Soliris (eculizumab) | ||||||||||||||||||||||||
| Ratings & Reviews | ||||||||||||||||||||||||||
|
Be the first to share your experience with this drug. |
Ultomiris has an average rating of 9.5 out of 10 from a total of 8 ratings on Drugs.com. 100% of reviewers reported a positive effect, while 0% reported a negative effect. |
Soliris has an average rating of 7.6 out of 10 from a total of 7 ratings on Drugs.com. 57% of reviewers reported a positive effect, while 14% reported a negative effect. |
||||||||||||||||||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | ||||||||||||||||||||||||||
|
View all Epysqli side effects |
View all Ultomiris side effects |
View all Soliris side effects |
||||||||||||||||||||||||
| Drug Class | ||||||||||||||||||||||||||
| Generic Availability | ||||||||||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||||||||||||||||||
View all Epysqli prices |
View all Ultomiris prices |
View all Soliris prices |
||||||||||||||||||||||||
| Dosage Forms | ||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||
| Brand Names | ||||||||||||||||||||||||||
| Other eculizumab brands include: Bkemv, Soliris |
N/A |
Other eculizumab brands include: Bkemv, Epysqli | ||||||||||||||||||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | ||||||||||||||||||||||||||
|
354 hours |
1192.8 hours |
354 hours |
||||||||||||||||||||||||
| CSA Schedule 1 View glossary of CSA terms | ||||||||||||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||||||||||
| Pregnancy Category | ||||||||||||||||||||||||||
|
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
||||||||||||||||||||||||
| Drug Interactions | ||||||||||||||||||||||||||
|
A total of 106 drugs are known to interact with Epysqli:
|
A total of 89 drugs are known to interact with Ultomiris:
|
A total of 106 drugs are known to interact with Soliris:
|
||||||||||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||||||||||
| Disease Interactions | ||||||||||||||||||||||||||
| First Approval Date | ||||||||||||||||||||||||||
|
July 19, 2024 |
December 21, 2018 |
March 16, 2007 |
||||||||||||||||||||||||
| WADA Class View classifications | ||||||||||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||||||||||
| More Information | ||||||||||||||||||||||||||
| Patient Resources | ||||||||||||||||||||||||||
| Professional Resources | ||||||||||||||||||||||||||
| Related Treatment Guide | ||||||||||||||||||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
See also:
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.